KIBRA attains oncogenic activity by repressing RASSF1A

Area of Science:

• Molecular Biology
• Cancer Research
• Cell Biology

Background:

• KIBRA, initially identified as a neuronal protein, is implicated in various cellular functions beyond the nervous system.
• KIBRA interacts with dynein light chain 1, crucial for estrogen receptor transactivation in breast cancer.
• KIBRA acts as a substrate for key kinases (Cdk1, Aurora, ERK), regulating cell cycle, proliferation, and migration.

Purpose of the Study:

• To investigate the role of KIBRA in breast cancer progression.
• To elucidate the molecular mechanisms underlying KIBRA's potential oncogenic activity.

Main Methods:

• KIBRA expression analyzed in breast tissues and cell lines using Western blotting, IHC, and RT-PCR.
• Stable KIBRA overexpression and knockdown cell lines generated to assess transforming properties.
• In vivo tumorigenic efficacy evaluated through xenograft studies in nude mice.
• Quantitative PCR array used to identify molecular targets of KIBRA.

Main Results:

• KIBRA is significantly upregulated in breast cancer cells and tumors, correlating with disease progression.
• Overexpression of KIBRA enhanced transforming properties in fibroblasts and breast cancer cells, while knockdown reduced them.
• Fibroblasts overexpressing KIBRA exhibited increased tumor-forming potential in vivo.
• RASSF1A, a known tumor suppressor, identified as a transcriptional target repressed by KIBRA.

Conclusions:

• This study provides the first evidence of KIBRA's in vivo tumorigenic capacity.
• KIBRA promotes cancer cell transformation by repressing the tumor suppressor RASSF1A.
• KIBRA represents a potential therapeutic target in breast cancer treatment.